Comparative Evaluation of 19 Reverse 1 Transcription Loop-Mediated Isothermal 2 Amplification Assays for Detection of 3 SARS-CoV-2 4 Yajuan Dong a, b[†], Xiuming Wu c[‡], Shenwei Li d, Renfei Lu e, Zhenzhou Wan f, 5 Jianru Qin b, Guoying Yu b, Xia Jin a, Chiyu Zhang a, c * 6 7 a Shanghai Public Health Clinical Center, Fudan University, Shanghai 201508, China; 8 9 b College of Life Sciences, Henan Normal University, Xinxiang 453007, China 10 c Pathogen Discovery and Evolution Unit, Institut Pasteur of Shanghai, Chinese Academy of 11 Sciences, Shanghai 200031, China 12 d Shanghai International Travel Healthcare Center, Shanghai 200335, China 13 e Clinical Laboratory, Nantong Third Hospital Affiliated to Nantong University, Nantong 14 226006, China; f Medical Laboratory of Taizhou Fourth People's Hospital, Taizhou 225300, China; 15 16 Running title: Evaluation of SARS-CoV-2 RT-LAMP assays. 17 18 *Corresponding author. 19 20 Prof. Chiyu Zhang, PhD, Pathogen Discovery and Evolution Unit, Institut Pasteur of 21 Shanghai, Chinese Academy of Sciences, 320 Yueyang Road, Shanghai, China. Tel: +86 21 5492 3051; E-mail address: zhangcy1999@ips.ac.cn 22 ‡ Yajuan Dong and Xiuming Wu contributed equally to this work. 23

24

Abstract

Coronavirus disease 2019 (COVID-19) caused by SARS-CoV-2 has caused a global pandemics. To facilitate the detection of SARS-CoV-2 infection, various RT-LAMP assays using 19 sets of primers had been developed, but never been compared. We performed comparative evaluation of the 19 sets of primers using 4 RNA standards and 29 clinical samples from COVID-19 patients. Six of 15 sets of primers were firstly identified to have faster amplification when tested with four RNA standards, and were further subjected to parallel comparison with the remaining four primer sets using 29 clinical samples. Among these 10 primer sets, Set-4 had the highest positive detection rate of SARS-CoV-2 (82.8%), followed by Set-10, Set-11, Set-13 and Set-14 (75.9%), and Set-14 showed the fastest amplification speed (< 8.5 minutes), followed by Set-17 (< 12.5 minutes). Based on the overall detection performance, Set-4, Set-10, Set-11, Set-13, Set-14 and Set-17 that target *Nsp3*, *S*, *S*, *E*, *N* and *N* gene regions of SARS-CoV-2, respectively, are determined to be better than the other primer sets. Two RT-LAMP assays with the Set-14 primers in combination with any one of four other primer sets (Set-4, Set-10, Set-11, and Set-13) are recommended to be used in the COVID-19 surveillance.

Keywords: COVID-19; SARS-CoV-2; LAMP; POCT; Clinical evaluation; Time threshold44 (Tt).

Introduction

46

47

48

49

50

51

52

53

54

55

56

57

58

59

60

61

62

63

64

65

66

67

68

69

70

Coronavirus disease 2019 (COVID-19), caused by the newly discovered coronavirus SARS-CoV-2 ^{1,2}, is rapidly spreading throughout the world, posing a huge challenge to global public health security. As of 1 June, 2020, it has infected over 6 million people, and resulted in at least 376,320 deaths globally. In the absence of effective antiviral drugs or efficacious vaccines, early diagnosis of SARS-CoV-2 infection is essential for the containment of COVID-19^{3,4}, without which it is impossible to timely implement intervention and quarantine measures, and difficult to track contacts in order to limit virus spread. Nucleic acid testing of various approaches are widely used as the primary tool for diagnosing COVID-19 ^{3,4}. Among them, real-time quantitative PCR (RT-qPCR) methods have been set as the gold standard for laboratory confirmation of SARS-CoV-2 infection because of their proven track record as being the most robust technology in molecular diagnostics ⁴⁻⁶. However, the RT-qPCR assay relies on sophisticated facilities with reliable supply of electricity and well-trained personnel in large general hospitals and health care facilities, or government labs (such as CDC), and it is relatively time-consuming (about 1.5-2 hrs). These limit its capacity in point-of-care settings. Moreover, visiting a clinical setting for testing increases the risk of spreading the virus. Therefore, an alternative, fast, simple, and sensitive point-of-care testing (POCT) is highly needed to facilitate the detection of SARS-CoV-2 infection in resource-limited settings ^{3,7}. Loop-mediated isothermal amplification (LAMP) is a promising POCT method with high sensitivity, specificity, and rapidity, and it is easy-to-use 8. To overcome the limitation of RT-qPCR assay, a number of RT-LAMP assays using at least 19 sets of different primers had been developed in the last few months for the detection of SARS-CoV-2 9-19. Although these assays had proven sensitive and effective for the detection of SARS-CoV-2, how do they compare with each other have not been evaluated. In this study, we compared all 19 sets of 71 SARS-CoV-2-specific RT-LAMP primers using the mismatch-tolerant LAMP system that is

faster and more sensitive than the conventional ones ^{20,21}, and screened the high-efficiency

RT-LAMP assays for use in the detection of field samples.

Results

72

73

74

75

76

77

78

79

80

81

82

83

84

85

86

87

88

89

90

94

Strategy for the comparative evaluation

There were 19 sets of SARS-CoV-2 RT-LAMP primers available for the evaluation. Among these primers, 2 sets were designed for binding to the Nsp3 (non-structural proteins), 5 for RdRp (RNA-dependent RNA polymerase), 2 for E (envelope protein) and 2 for N (nucleocapsid protein) gene regions of SARS-CoV-2 (Fig. 1). These regions are highly conserved among SARS-CoV-2 and SARS-CoV, but distinct from five other human coronaviruses (MERS-CoV, OC43, 229E, NL63 and HKU1). Other 4 sets of primers were dispersed throughout the genome of SARS-CoV-2. The primers binding to the same target gene are adjacent to each other and cover genomic segments from 251 to 1954 bps. To minimize the consumption of clinical samples, and economize experimental efforts, we adopted a strategy that initiated by a preliminary evaluation of the primers binding to the four major genomic regions using in vitro-transcribed RNA standard, and followed by a further evaluation of preliminarily selected primers together with four sets of other primers using clinical RNA samples (Fig. 1).

Preliminary evaluation of primer sets

Using 3000 copies of in vitro-transcribed RNA standards of four gene segments of 91 92 SARS-CoV-2, we assessed the amplification performance of 15 sets of RT-LAMP primers. 93 Except for Set-3 that failed in amplification, all other primer sets generated amplification curves with Time threshold (Tt) of 7.5-15.9 minutes and reached the plateau phase within 20

minutes (Fig. 2). In particular, six sets of the primers showed faster amplification with 10 minutes less Tt values than other primer sets (Fig. 2), implying higher amplification sensitivity. The six sets (Set-2, Set-5, Set-13, Set-14, Set-17 and Set-18) of primers contain three that bind to N gene and another three that bind to Nsp, RdRp, and E genes, respectively. The six sets of primers were selected for further evaluation using clinical samples together with other four primer sets that bind to other genomic regions of the virus.

Comparative evaluation of ten primer sets using clinical samples

95

96

97

98

99

100

101

102

103

104

105

106

107

108

109

110

111

112

113

114

115

116

117

118

A total of 29 RNA samples extracted from COVID-19 patients were used at 4-fold dilutions. Except for one, all 29 RNA samples were detected as being SARS-CoV-2 positive by at least one of the primer sets. Nine samples were detected as positive by all ten sets of primers and almost all reactions (except for one with 49.5 minutes) had Tt values of less than 15.1 minutes, indicating a high viral load. The primer Set-4 detected 24 positive samples, showing the highest positive detection rate (82.8%), followed by Set-10, Set-11, Set-13 and Set-17 that all detected 22 positive samples (75.9%) (Fig. 3A). Two primer sets, Set-1 and Set-18, had the lowest positive detection rates of 44.8% and 62.1%, respectively, and thus were excluded in the subsequent analyses. Comparison showed that the primer Set-14 had the lowest mean Tt values of less than 8.4 minutes, followed by Set-10, Set-11 and Set-13 that had mean Tt values of 11.1-11.5 minutes (Fig. 3A). These four fast-amplification sets of primers also have small standard deviations (SD) of 1.7-2.9, indicating that the RT-LAMP with these four primer sets are relatively more stable and faster than the other 15 sets. As expected, the primer Set-14 is the most efficient one that generated the fastest (the lowest Tt value) and the second fastest amplification in 14 and 7 samples, followed by Set-17 which is the fastest in 6 samples and second best in 9 samples, demonstrating these two primer sets had the best performance.

Because of their relatively high positive detection rate and lower Tt values, six primer sets including Set-4, Set-10, Set-11, Set-13, Set-14 and Set-17 were subjected to further pairwise comparison. The comparison showed that any two sets of these primers had high concordance performance (87.8-97.6%) for 41 clinical RNA samples (including 29 positive and 12 negative for SARS-CoV-2) (Fig. 3B). All the six primer sets had high amplification efficiency with mean Tt values of less than 12 minutes (Fig. 3B). In particular, Set-14 had faster amplification than the other five sets of primers (8.3-8.4 vs. 10.5-11.2 minutes).

Specficity evaluation of four optimal primer sets based on sequence alignment

The specificity of these primer sets had been reported in previous studies ⁹⁻¹⁹. In this evaluation, all ten primer sets did not generate amplification for all 12 COVID-19 negative RNA samples. To further examine the specificity of six recommended primer sets (Set-4, Set-10, Set-11, Set-13, Set-14 and Set-17) to other human coronaviruses, we performed sequence alignment analyses. SARS-CoV-2 shared 79.5% genomic homology with SARS-CoV ^{1,2}, indicating a relatively high sequence identity; but it was largely distinct from MERS-CoV and other four human coronaviruses (Supplementary Fig. S1). In particular, several primers of Set-4, Set-10 and Set-17 correspond to gaps or insertions of the genomes of MERS-CoV and other four common human coronaviruses OC43, 229E, NL63 and HKU1. These results implied that these six sets of primers were unable to bind to the genomes of MERS-CoV and four common human coronaviruses, therefore more specific for SARS-CoV-2. However, because of high sequence identity and the use of mismatch-tolerant RT-LAMP system that allows the presence of few mismatched bases between primers and templates, the SARS-CoV-2 RT-LAMP assays may generate a cross-amplification of SARS-CoV.

Discussion

144

145

146

147

148

149

150

151

152

153

154

155

156

157

158

159

160

161

162

163

164

165

166

167

169

170

171

172

173

174

175

176

177

178

179

180

181

182

183

184

185

186

187

188

189

190

191

192

194

195

196

197

198

199

200

201

202

203

204

205

206

207

208

209

210

211

212

213

214

215

216

217

recommended to be used in the COVID-19 surveillance to facilitate the early finding of

Materials and Methods

Ethics Statement

218

219

220

221

222

226

228

229

230

231

232

233

234

235

236

237

238

239

223 The study was approved by Nantong Third Hospital Ethics Committee (E2020002: 3 224 February 2020). All experiments were performed in accordance with relevant guidelines and 225 regulations. Written informed consents were obtained from each of the involved patients.

Preparation of RNA standard

227 To prepare RNA standard, four SARS-CoV-2 genomic segments (2720-3620 nt, 13403-15502 nt, 25901-26700 nt and 28274-29533 nt in Wuhan-Hu-1, GenBank: MN908947.3) were amplified from previously confirmed positive RNA sample with T7-promoter-containing primers (Supplementary Table S1). RNA standard was generated by in vitro transcription, and quantitated by Qubit® 4.0 Fluorometer (Thermo Fisher Scientific, USA). Copy number of RNA standard was estimated using the formula: RNA copies/ml = [RNA concentration (g/ μ L)/(nt transcript length × 340)] × 6.022 × 10²³.

RNA samples of COVID-19 patients

A total of 29 RNA samples were obtained from COVID-19 patients described in our previous studies ^{9,10}. In brief, RNA was extracted from 300 µL throat swabs of COVID-19 patients using RNA extraction Kit (Liferiver, Shanghai) and eluted in 90 µL nuclease-free water. After screening and confirmation tests, the remaining RNA samples were stored at -80°C. When used for RT-LAMP assays, the stored SARS-CoV-2 positive RNA samples as

confirmed by RT-qPCR assay were thawed and 4-fold diluted. In addition, 12 SARS-CoV-2

negative clinical RNA samples were used as controls. .

RT-LAMP Assay

241

242

243

244

245

246

247

248

249

250

251

252

253

254

255

256

To assess the performance of 19 sets of RT-LAMP primers in the detection of SARS-CoV-2, an optimized mismatch-tolerant RT-LAMP method that has higher sensitivity and faster amplification speed than the conventional ones was used. A 25 μL RT-LAMP reaction mixture was prepared with 1x isothermal amplification buffer, 6 mM MgSO4, 1.4 mM dNTPs, 8 units of WarmStart Bst 2.0 DNA polymerase, 7.5 units of WarmStartR RT, 0.15 unit of Q5 High-Fidelity DNA Polymerase, 0.2 μM each of primers of F3 and B3, 1.6 μM each of primers of FIP and BIP, 0.4 μM each of loop primer LF and/or LB, and 0.4 mM SYTO 9 (Life technologies, Carlsbad, CA, United States). The enzymes were all purchased from New England Biolabs (Beverly, MA, United States). In general, 3 μL of RNA standard or samples were added into each RT-LAMP reaction. The reaction was run at 63 □ for 50 minutes with real-time monitoring by the LightCycler 96 real-time PCR System (Roche Diagnostics, Mannheim, Germany).

Reference

- Zhu, N. et al. A Novel Coronavirus from Patients with Pneumonia in China, 2019. N Engl J
 Med 382, 727-733, doi:10.1056/NEIMoa2001017 (2020).
- Zhou, P. *et al.* A pneumonia outbreak associated with a new coronavirus of probable bat origin. *Nature* **579**, 270-273, doi:10.1038/s41586-020-2012-7 (2020).
- Udugama, B. *et al.* Diagnosing COVID-19: The Disease and Tools for Detection. *ACS Nano* 14,
 3822-3835, doi:10.1021/acsnano.0c02624 (2020).
- Lo, Y. M. D. & Chiu, R. W. K. Racing Towards the Development of Diagnostics for a Novel Coronavirus (2019-nCoV). *Clin Chem* **66**, 503-504, doi:10.1093/clinchem/hvaa038 (2020).
- 265 Chu, D. K. W. *et al.* Molecular Diagnosis of a Novel Coronavirus (2019-nCoV) Causing an Outbreak of Pneumonia. *Clin Chem* **66**, 549-555, doi:10.1093/clinchem/hvaa029 (2020).
- Li, Y. *et al.* A mismatch-tolerant RT-quantitative PCR: application to broad-spectrum detection of respiratory syncytial virus. *Biotechniques* **66**, 225-230, doi:10.2144/btn-2018-0184 (2019).

- 270 7 Nguyen, T., Duong Bang, D. & Wolff, A. 2019 Novel Coronavirus Disease (COVID-19):
- Paving the Road for Rapid Detection and Point-of-Care Diagnostics. *Micromachines (Basel)* 11,
- 272 doi:10.3390/mi11030306 (2020).
- Notomi, T. et al. Loop-mediated isothermal amplification of DNA. Nucleic Acids Res 28, E63,
- 274 doi:10.1093/nar/28.12.e63 (2000).
- 275 9 Lu, R. et al. Development of a Novel Reverse Transcription Loop-Mediated Isothermal
- 276 Amplification Method for Rapid Detection of SARS-CoV-2. Virol Sin,
- 277 doi:10.1007/s12250-020-00218-1 (2020).
- 278 10 Lu, R. et al. A Novel Reverse Transcription Loop-Mediated Isothermal Amplification Method
- 279 for Rapid Detection of SARS-CoV-2. *Int J Mol Sci* **21**, doi:10.3390/ijms21082826 (2020).
- 280 11 Yu, L. et al. Rapid detection of COVID-19 coronavirus using a reverse transcriptional
- loop-mediated isothermal amplification (RT-LAMP) diagnostic platform. Clin Chem,
- 282 doi:10.1093/clinchem/hvaa102 (2020).
- 283 12 Yan, C. et al. Rapid and visual detection of 2019 novel coronavirus (SARS-CoV-2) by a reverse
- transcription loop-mediated isothermal amplification assay. Clin Microbiol Infect,
- 285 doi:10.1016/j.cmi.2020.04.001 (2020).
- Mohamed, E.-T., Haim H., B. & Jinzhao, S. A Single and Two-Stage, Closed-Tube, Molecular Test
- for the 2019 Novel Coronavirus (COVID-19) at Home, Clinic, and Points of Entry. (2020).
- 288 14 Park, G. S. et al. Development of Reverse Transcription Loop-Mediated Isothermal
- Amplification Assays Targeting SARS-CoV-2. J Mol Diagn, doi:10.1016/j.jmoldx.2020.03.006
- 290 (2020).
- 291 15 Broughton, J. P. et al. Rapid Detection of 2019 Novel Coronavirus SARS-CoV-2 Using a
- 292 CRISPR-based DETECTR Lateral Flow Assay. medRxiv, 2020.2003.2006.20032334,
- 293 doi:10.1101/2020.03.06.20032334 (2020).
- 294 16 Yang, W. et al. Rapid Detection of SARS-CoV-2 Using Reverse transcription RT-LAMP
- 295 method. medRxiv, 2020.2003.2002.20030130, doi:10.1101/2020.03.02.20030130 (2020).
- 296 17 Jiang, M. et al. Development and validation of a rapid single-step reverse transcriptase
- loop-mediated isothermal amplification (RT-LAMP) system potentially to be used for
- reliable and high-throughput screening of COVID-19. medRxiv, 2020.2003.2015.20036376,
- 299 doi:10.1101/2020.03.15.20036376 (2020).
- 300 18 Zhang, Y. et al. Rapid Molecular Detection of SARS-CoV-2 (COVID-19) Virus RNA Using
- 301 Colorimetric LAMP. *medRxiv*, 2020.2002.2026.20028373, doi:10.1101/2020.02.26.20028373
- 302 (2020).
- 303 19 Lamb, L. E., Bartolone, S. N., Ward, E. & Chancellor, M. B. Rapid Detection of Novel
- 304 Coronavirus (COVID-19) by Reverse Transcription-Loop-Mediated Isothermal Amplification.
- 305 *medRxiv*, 2020.2002.2019.20025155, doi:10.1101/2020.02.19.20025155 (2020).
- 306 20 Zhou, Y. et al. A Mismatch-Tolerant Reverse Transcription Loop-Mediated Isothermal
- 307 Amplification Method and Its Application on Simultaneous Detection of All Four Serotype of
- 308 Dengue Viruses. Front Microbiol 10, 1056, doi:10.3389/fmicb.2019.01056 (2019).
- 309 21 Li, Y. et al. A Mismatch-tolerant RT-LAMP Method for Molecular Diagnosis of Highly
- 310 Variable Viruses. *Bio-protocol* 9, e3415, doi:10.21769/BioProtoc.3415 (2019).
- 311 22 Wang, W. et al. Detection of SARS-CoV-2 in Different Types of Clinical Specimens. JAMA,
- 312 Online ahead of print, doi:10.1001/jama.2020.3786 (2020).
- 313 Zou, L. et al. SARS-CoV-2 Viral Load in Upper Respiratory Specimens of Infected Patients. N

The authors report no conflicts of interest in this work.

Figure 1. Genome location and evaluation strategy of 19 sets of SARS-CoV-2 RT-LAMP primers. The location of each primer set was detailed in Table 1. SD: standard deviation.

Figure 2. Comparison of performance of 15 RT-LAMP assays using RNA standards. The curves of non-template control (NTC) are not shown. * The Tt values of the Set-8 were obtained by another repeated comparative experiments with Set-5and Set-9, both of which showed a consistent trend, but slightly lower Tt values than those shown here.

Figure 3. Comparison of performance of 10 selected RT-LAMP primer sets using 41 clinical RNA samples. A. Positive rates and Tt values of 10 selected RT-LAMP assays. B. Paired comparison of Tt values of the primers Set-4, Set-10, Set-11, Set-13, Set-14 and Set-17.

Table 1 Information of 19 sets of RT-LAMP primers for the detection of SARS-CoV-2.

| Primer | | rmation of 19 sets of RT-LAMP primers for the d Primer sequence (5'-3') | Target | Genomic | Sensitivity | Refs |
|--------|-----------|--|---------|---------------|------------------|------|
| sets | name | | gene | location (nt) | (LOD) | |
| S1 | F3 | CTGCACCTCATGGTCATGTT | orf1ab | 498-711 | 1200 | (18) |
| 31 | В3 | AGCTCGTCGCCTAAGTCAA | Oljiub | 430 711 | copies/25 | (10) |
| | FIP | GAGGGACAAGGACACCAAGTGTATGGTTGAGCTGGTAGCAGA | | | μL | |
| | BIP | CCAGTGGCTTACCGCAAGGTTTTAGATCGGCGCCGTAAC | | | reaction | |
| | LF | CCGTACTGAATGCCTTCGAGT | | | | |
| | LB | TTCGTAAGAACGGTAATAAAGGAGC | | | | |
| S2 | F3 | TCCAGATGAGGATGAAGAAGA | orf1ab | 3043-3331 | 1.02 fg/25 | (19) |
| 32 | В3 | AGTCTGAACAACTGGTGTAAG | Oljiub | 3043 3331 | μL | (13) |
| | FIP | AGAGCAGCAGAAGTGGCACAGGTGATTGTGAAGAAGAAGAAGA | | | reaction | |
| | BIP | TCAACCTGAAGAAGAGCAAGAACTGATTGTCCTCACTGCC | | | | |
| | LF | CTCATATTGAGTTGATGGCTCA | | | | |
| | LB | ACAAACTGTTGGTCAACAAGAC | | | | |
| \$3 | F3 | | auf1auh | 2145 2245 | 100 | /14\ |
| 33 | | GGAATTTGGTGCAATACTCTCAACA | orf1ab | 3145-3345 | copies/15 | (14) |
| | B3 FIP | CTATTCACTTCAATAGTCTGAACA CTTGTTGACCAACAGTTTGTTGACTTCAACCTGAAGAAGAAGAACAA | | | μL | |
| | | | | | reaction | |
| | BIP | CGGCAGTGAGGAATCATCTTC | | | | |
| | LF | ATCATCATCTAACCAATCTTCTTC | | | | |
| | LB | TCAAACAATTGTTGAGGTTCAACC | | | 100 | |
| S4 | F3 | TGCAACTAATAAAGCCACG | orf1ab | 6253-6446 | 100 copies/15 | (14) |
| | B3 | CGTCTTTCTGTATGGTAGGATT | (Nsp3) | | μL | |
| | FIP | TCTGACTTCAGTACATCAAACGAATAAATACCTGGTGTATACGTTGTC | | | reaction | |
| | BIP | GACGCGCAGGGAATGGATAATTCCACTACTTCTTCAGAGACT | | | | |
| | LF | TGTTTCAACTGGTTTTGTGCTCCA | | | | |
| | LB | TCTTGCCTGCGAAGATCTAAAAC | | | | |
| S5 | F3 | TGCTTCAGTCAGCTGATG | orf1ab | 13434-13636 | 7 copies/10 | (13) |
| | В3 | TTAAATTGTCATCTTCGTCCTT | | | μl reaction | |
| | FIP | TCAGTACTAGTGCCTGTGCCCACAATCGTTTTTAAACGGGT | | | | |
| | BIP | TCGTATACAGGGCTTTTGACATCTA TCTTGGAAGCGACAACAA | | | | |
| | LF | CTGCACTTACACCGCAA | | | | |
| | LB | GTAGCTGGTTTTGCTAAATTCC | | | | |
| S6 | F3 | GGTATGATTTTGTA GAAAACCCA | orf1ab | 13925-14140 | 20 copies/25 | (12) |
| | В3 | CAACAGGAACTCCACTACC | | | μl | |
| | FIP | GGCATCACAGAATTGTACTGTTTTTGCGTATACGCCAACTTAGG | | | reaction | |
| | BIP | AATGCTGGTATTGTTGGTGTACTGAGGTTTGTATGAAATCACCGAA | | | | |
| | LF | AACAAAGCTTGGCGTACACGTTCA | | | | |
| S7 | F3 | GTTACGATGGTGGCTGTA | orf1ab | 14885-15081 | 5 | (16) |
| | В3 | GGCATACTTAAGATTCATTTGAG | | | copies/25 µl | |
| | FIP | AGCCTTACCCCATTTATTAAATGGAGCTAACCAAGTCATCGTCAA | | | reaction | |
| | BIP | AATGAGTTATGAGGATCAAGATGCATTATAGTAGGGATGACATTACGT | | | | |
| | LF | AAACCAGCTGATTTGTCTAGGTTG | | | | |

| LF GGACTGAGATCTTTCATTTTACCGT | | |
|--|--------------------|------|
| 15 1.570.000.000770.1710. | | |
| LB ACTGAGGGAGCCTTGAATACA | | |
| S16 F3 AGATCACATTGGCACCCG N 28702-28914 | | (16) |
| B3 CCATTGCCAGCCATTCTAGC | copies/25 μL | |
| FIP TGCTCCCTTCTGCGTAGAAGCCAATGCTGCAATCGTGCTAC | reaction | |
| BIP GGCGGCAGTCAAGCCTCTTCCCTACTGCTGCAGTT | | |
| LF GCAATGTTGTTCCTTGAGGAAGTT | | |
| LB CGTAGTCGCAACAGTTAAGAAATTC | | |
| S17 F3 GCCAAAAGGCTTCTACGCA N 28774-28971 | NA | (14) |
| B3 TTGCTCTCAAGCTGGTTCAA | | |
| FIP TCCCCTACTGCTGCAGGCAGTCAAGCCTCTTCTCG | | |
| BIP TCTCCTGCTAGAATGGCTGGCATCTGTCAAGCAGCAAAG | | |
| LF TGTTGCGACTACGTGATGAGGA | | |
| LB ATGGCGGTGATGCTCT | | |
| S18 F3 GCCAAAAGGCTTCTACGCA N 28774-28971 | | (10) |
| B3 TTGCTCTCAAGCTGGTTCAA | /25 µL reaction | |
| FIP TCCCCTACTGCTGGAGCAGTCAAGCCTCTTCTCGTT | (118.6 | |
| BIP TCTCCTGCTAGAATGGCTGGCATCTGTCAAGCAGCAGCAAAG | copies/25 | |
| LB TGGCGGTGATGCTCTT | μL reaction) | |
| S19 F3 AACACAAGCTTTCGGCAG N 29083-29311 | 20 | (15) |
| B3 GAAATTTGGATCTTTGTCATCC | copies/10 | |
| FIP CGCATTGGCATGGAAGTCACTTTGATGGCACCTGTGTAG | μL reaction | |
| BIP TGCGGCCAATGTTTGTAATCAGCCAAGGAAATTTTGGGGAC | | |
| LF TTCCTTGTCTGATTAGTTC | | |
| LB ACCTTCGGGAACGTGGTT | | |

Notes: F3/B3: outer primers; FIP/BIP: forward and backward internal primers; LF/LB:

forward and backward loop primers.




Figure 1. Genome location and evaluation strategy of 19 sets of SARS-CoV-2 RT-LAMP primers. The location of each primer set was detailed in Table 1.





Figure 2. Comparison of performance of 15 RT-LAMP assays using RNA standards. The curves of non-template control (NTC) are not shown. * The Tt values of the Set-8 were obtained by another repeated comparative experiments with Set-5 and Set-9, both of which showed a consistent trend, but slightly lower Tt values than those shown here.



| _ | _ |
|---|----|
| П | т. |
| н | v |
| | |
| | |

| Primer set | Set-4 | Set-10 | Set-4 | Set-11 | Set-4 | Set-13 | Set-4 | Set-14 | Set-4 | Set-17 |
|-------------------------|--------|--------|--------|--------|-------------|--------|---------------|---------------|--------|--------|
| Mean Tt (mins) | 10.8 | 11.1 | 10.8 | 11.3 | 10.9 | 11.5 | 10.7 | 8.3 | 11.5 | 12.0 |
| Paired positive | | | | | | | | | 2. | |
| number | 21 | | 21 | | 22 | | 20 | | 21 | |
| Concordance rate | 90. | .2% | 90.2% | | 95.1% | | 87.8% | | 90.2% | |
| | | | | | | | | | | |
| Primer set | Set-10 | Set-11 | Set-10 | Set-13 | Set-10 | Set-14 | Set-10 | Set-17 | Set-11 | Set-13 |
| Mean Tt (mins) | 11.1 | 11.3 | 11.1 | 11.4 | 11.1 | 8.4 | 11.1 | 10.7 | 11.3 | 11.4 |
| Paired positive | | | | | | | | | | |
| number | 2 | 21 | 21 | | 21 | | 21 | | 21 | |
| Concordance rate | 95. | .1% | 95. | 1% | 97.6% 95.1% | | 1% | 95.1% | | |
| | | | | | | | | | | |
| Primer set | Set-11 | Set-14 | Set-11 | Set-17 | Set-13 | Set-14 | Set-14 | Set-17 | | |
| Mean Tt (mins) | 11.2 | 8.3 | 11.2 | 10.1 | 11.1 | 8.3 | 8.3 | 10.5 | | |
| Paired positive | | | | | | | | | | |
| number | 2 | 20 | 2 | 20 | 20 | | 20 | | | |
| Concordance rate | 92. | .7% | 90. | 2% | 92.7 | 7% | 92. | .7% | | |

Figure 3. Comparison of performance of 10 selected RT-LAMP primer sets using 41 clinical RNA samples. A. Positive rates and Tt values of 10 selected RT-LAMP assays. B. Paired comparison of Tt values of the primers Set-4, Set-10, Set-11, Set-13, Set-14 and Set-17.